QR Code

The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer

Abstract Activating antibody-dependent cellular cytotoxicity (ADCC) by targeting claudin-18 isoform 2 (CLDN18.2) using zolbetuximab, a monoclonal antibody against CLDN18.2, has been considered a promising novel therapeutic strategy for gastric cancer (GC). However, the impact of CLDN18.2 expression...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Akira Matsuishi, Shotaro Nakajima, Motonobu Saito, Katsuharu Saito, Satoshi Fukai, Hideaki Tsumuraya, Ryo Kanoda, Tomohiro Kikuchi, Azuma Nirei, Akinao Kaneta, Hirokazu Okayama, Kosaku Mimura, Hiroyuki Hanayama, Wataru Sakamoto, Tomoyuki Momma, Zenichiro Saze, Koji Kono
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Nature Portfolio 2024-08-01
Rangatū:Scientific Reports
Ngā marau:
Gastric cancer
CLDN18.2
NK cells
Monocytes/macrophages
Urunga tuihono:https://doi.org/10.1038/s41598-024-68970-y
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite